VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
USNAUSANA Health Sciences, Inc.
$20.70$382M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksUSNAFinancials

USANA Health Sciences, Inc. (USNA) Financials

30Y historyFree accessUpdated daily

Operating margins have compressed significantly to 5.5% in 2026Q1, reflecting a disconnect between robust 76.2% gross margins and bottom-line profitability.

USNA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMJan'26Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue925.94M925.26M854.5M921.01M998.6M1.19B1.13B1.06B1.19B1.05B1.01B918.5M790.47M718.17M648.73M581.94M517.64M436.94M429.01M423.15M374.19M327.74M272.82M200.01M133.78M114.28M123.18M129.4M121.6M85.2M56.7M
Revenue Growth %5.67%8.28%-7.22%-7.77%-15.83%4.57%6.95%-10.79%13.56%4.09%9.54%16.2%10.07%10.71%11.48%12.42%18.47%1.85%1.39%13.08%14.17%20.13%36.4%49.51%17.06%-7.23%-4.81%6.41%42.72%50.26%131.43%
Cost of Goods Sold215.59M200.85M175.75M189.4M207.28M230.93M222.86M202.03M217.44M195.36M193.67M169.66M149.6M136.48M124.63M110.17M103.4M96.87M95.58M93.22M95.11M83.92M71.66M44.42M33.39M32.8M32.16M21M21.9M15.6M10.8M
COGS % of Revenue-21.71%20.57%20.56%20.76%19.46%19.64%19.04%18.28%18.65%19.25%18.47%18.93%19%19.21%18.93%19.97%22.17%22.28%22.03%25.42%25.61%26.27%22.21%24.96%28.7%26.11%16.23%18.01%18.31%19.05%
Gross Profit710.35M724.4M678.75M731.62M791.32M955.53M911.79M858.87M971.81M851.9M812.41M748.84M640.87M581.7M524.1M471.77M414.25M340.07M333.44M329.93M279.08M243.82M201.16M155.59M100.38M81.48M91.02M108.4M99.7M69.6M45.9M
Gross Margin %76.72%78.29%79.43%79.44%79.24%80.54%80.36%80.96%81.72%81.35%80.75%81.53%81.07%81%80.79%81.07%80.03%77.83%77.72%77.97%74.58%74.39%73.73%77.79%75.04%71.3%73.89%83.77%81.99%81.69%80.95%
Gross Profit Growth %-6.73%-7.23%-7.54%-17.19%4.8%6.16%-11.62%14.08%4.86%8.49%16.85%10.17%10.99%11.09%13.89%21.81%1.99%1.06%18.22%14.46%21.21%29.29%55%23.2%-10.49%-16.03%8.73%43.25%51.63%140.31%
Operating Expenses661.28M673.54M612.43M638.54M683.7M785.34M735.29M712.68M783.46M719.4M673.79M607.18M524.76M464.98M425.92M394.52M346.03M289.28M285.44M259.22M216.74M185.46M156.32M124.47M87.59M77.28M85.57M94.4M84.5M59M38M
OpEx % of Revenue-72.8%71.67%69.33%68.47%66.19%64.8%67.18%65.88%68.69%66.97%66.11%66.39%64.75%65.65%67.79%66.85%66.21%66.53%61.26%57.92%56.59%57.3%62.23%65.48%67.62%69.47%72.95%69.49%69.25%67.02%
Selling, General & Admin413.49M337.37M600.86M627.1M672.14M774.23M724.66M702.42M773.22M710.45M664.95M600.76M519.64M459.9M421.25M390.45M342.19M285.65M282.14M255.86M213.54M183.12M154.28M123.09M86.56M76.2M79.97M88.5M79.7M55.6M36.4M
SG&A % of Revenue-36.46%70.32%68.09%67.31%65.25%63.87%66.21%65.02%67.84%66.09%65.41%65.74%64.04%64.94%67.09%66.1%65.38%65.77%60.47%57.07%55.87%56.55%61.54%64.7%66.68%64.92%68.39%65.54%65.26%64.2%
Research & Development0011.57M11.45M11.56M11.11M10.63M10.26M10.24M8.95M8.84M6.42M5.13M5.08M4.66M4.07M3.84M3.63M3.3M3.36M3.2M2.34M2.03M1.38M1.03M1.08M1.41M1.4M1.4M1.2M800K
R&D % of Revenue--1.35%1.24%1.16%0.94%0.94%0.97%0.86%0.85%0.88%0.7%0.65%0.71%0.72%0.7%0.74%0.83%0.77%0.79%0.85%0.71%0.74%0.69%0.77%0.95%1.14%1.08%1.15%1.41%1.41%
Other Operating Expenses3M336.17M0000000000000000000000004.19M4.5M3.4M2.2M800K
Operating Income49.06M50.86M66.32M93.07M107.61M170.19M176.49M146.19M188.35M132.5M138.62M141.66M116.1M116.71M98.18M77.26M68.22M50.79M48M70.7M62.34M58.36M44.85M31.12M12.79M4.2M5.46M14M15.2M10.6M7.9M
Operating Margin %5.3%5.5%7.76%10.11%10.78%14.34%15.55%13.78%15.84%12.65%13.78%15.42%14.69%16.25%15.13%13.28%13.18%11.62%11.19%16.71%16.66%17.81%16.44%15.56%9.56%3.68%4.43%10.82%12.5%12.44%13.93%
Operating Income Growth %--23.31%-28.74%-13.51%-36.77%-3.57%20.73%-22.39%42.15%-4.41%-2.15%22.02%-0.52%18.88%27.08%13.25%34.31%5.82%-32.11%13.41%6.82%30.14%44.11%143.25%204.6%-23.01%-61.04%-7.89%43.4%34.18%125.71%
EBITDA88.31M90.56M88.55M113.47M129.02M192.38M199M168.98M205.08M148.46M152.1M151.64M124.91M125.76M107M85.73M76.13M57.86M54.69M76.03M67.91M64.27M49.69M35M16.93M8.32M9.64M18.5M18.6M12.8M8.7M
EBITDA Margin %9.54%9.79%10.36%12.32%12.92%16.21%17.54%15.93%17.24%14.18%15.12%16.51%15.8%17.51%16.49%14.73%14.71%13.24%12.75%17.97%18.15%19.61%18.21%17.5%12.66%7.28%7.83%14.3%15.3%15.02%15.34%
EBITDA Growth %4.25%2.27%-21.96%-12.06%-32.93%-3.32%17.76%-17.6%38.13%-2.39%0.31%21.4%-0.67%17.52%24.82%12.61%31.58%5.79%-28.07%11.97%5.66%29.35%41.98%106.71%103.58%-13.74%-47.89%-0.54%45.31%47.13%128.95%
D&A (Non-Cash Add-back)39.25M39.7M22.23M20.39M21.41M22.19M22.51M22.79M16.73M15.96M13.48M9.98M8.81M9.04M8.83M8.47M7.92M7.07M6.7M5.33M5.56M5.9M4.84M3.88M4.14M4.12M4.19M4.5M3.4M2.2M800K
EBIT40.92M42.37M76.63M102.72M108.81M170.7M178.46M146.19M191.55M134.69M138.62M141.66M116.1M116.71M98.45M77.49M68.96M51.59M47.11M70.7M63.7M60.14M62.34M31.12M12.79M4.2M5.46M14.01M15.22M10.6M7.9M
Net Interest Income1.46M1.57M11.04M9.38M3.6M2.46M2.03M4.64M4.39M2.14M1.04M1.1M371K463K227K182K73K-527K-543K000000000000
Interest Income2.13M2.42M11.32M9.64M3.79M2.52M2.54M4.71M4.43M2.19M1.48M1.12M500K464K247K191K167K82K249K000572K00000000
Interest Expense671K842K281K262K192K57K507K66K36K46K444K15K129K1K20K9K94K609K792K000000000000
Other Income/Expense-8.81M-9.34M10.03M9.38M1.01M450K1.46M4.31M3.16M2.14M-70K927K-449K-131K247K222K648K187K-1.68M471K1.41M487K233K192K-221K-692K-677K-4.45M200K100K200K
Pretax Income40.25M41.53M76.35M102.45M108.62M170.64M177.95M150.5M191.51M134.64M138.55M142.59M115.65M116.58M98.43M77.48M68.86M50.98M46.32M71.17M63.75M58.85M45.08M31.31M12.57M3.51M4.78M9.6M15.4M10.7M8.1M
Pretax Margin %4.35%4.49%8.94%11.12%10.88%14.38%15.68%14.19%16.1%12.86%13.77%15.52%14.63%16.23%15.17%13.31%13.3%11.67%10.8%16.82%17.04%17.96%16.52%15.65%9.4%3.07%3.88%7.42%12.66%12.56%14.29%
Income Tax31.11M30.05M34.29M38.66M39.27M54.14M53.28M49.97M65.29M72.11M38.51M47.92M39.02M37.56M31.99M26.73M23.21M17.42M16.38M25.24M22.49M19.86M14.3M10.49M4.07M1.31M1.91M3.7M5.9M4.1M3.1M
Effective Tax Rate %77.28%72.36%44.91%37.74%36.15%31.73%29.94%33.2%34.09%53.55%27.8%33.6%33.74%32.22%32.5%34.49%33.71%34.18%35.35%35.47%35.27%33.74%31.73%33.52%32.37%37.31%40%38.54%38.31%38.32%38.27%
Net Income8.87M10.76M42.03M63.79M69.35M116.5M124.66M100.53M126.22M62.53M100.04M94.67M76.64M79.02M66.43M50.75M45.65M33.56M29.95M45.32M41.27M38.99M30.78M20.82M8.5M2.2M2.87M5.9M9.5M6.6M5M
Net Margin %0.96%1.16%4.92%6.93%6.94%9.82%10.99%9.48%10.61%5.97%9.94%10.31%9.7%11%10.24%8.72%8.82%7.68%6.98%10.71%11.03%11.9%11.28%10.41%6.36%1.92%2.33%4.56%7.81%7.75%8.82%
Net Income Growth %-74.59%-74.4%-34.11%-8.02%-40.47%-6.54%24.01%-20.36%101.85%-37.49%5.67%23.53%-3.02%18.95%30.9%11.17%36.04%12.06%-33.92%9.82%5.83%26.7%47.85%144.82%286.68%-23.3%-51.41%-37.89%43.94%32%117.39%
Net Income (Continuing)9.15M11.48M42.06M63.79M69.35M116.5M124.66M100.53M126.22M62.53M100.04M94.67M76.64M79.02M66.43M50.75M45.65M33.56M29.95M45.93M41.27M38.99M30.78M20.82M8.5M2.2M2.87M5.9M9.5M6.6M5M
Discontinued Operations0000000000000000000000000000000
Minority Interest51.24M53.17M54.22M0000000000000000000000000000
EPS (Diluted)0.480.582.193.303.595.735.864.415.122.533.993.592.802.782.231.631.431.090.931.321.100.990.760.490.210.060.070.120.170.120.10
EPS Growth %-74.01%-73.52%-33.64%-8.08%-37.35%-2.22%32.88%-13.87%102.37%-36.59%11.14%28.21%0.72%24.66%36.81%13.99%31.19%17.2%-29.55%20%11.11%30.26%55.1%133.33%265.22%-20.69%-39.58%-29.41%41.67%26.32%90%
EPS (Basic)-0.582.203.333.605.785.894.445.362.604.093.713.112.852.401.701.431.100.941.361.151.030.810.550.230.060.070.120.180.130.10
Diluted Shares Outstanding18.41M18.57M19.16M19.34M19.31M20.34M21.26M22.82M24.64M24.71M25.05M26.35M27.38M28.41M29.85M31.15M31.88M30.86M32.33M34.41M37.45M39.44M40.83M42.64M41.29M38.82M39.56M49.89M55.72M53.28M52.63M
Basic Shares Outstanding18.4M18.57M19.06M19.25M19.25M20.15M21.04M22.64M23.57M24.02M24.48M24.98M25.27M27.77M27.64M29.88M30.62M30.7M32.1M33.47M36.11M37.75M38.33M38.04M37.77M38.71M39.15M48.63M51.75M50.96M50M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetFortress
Cash FlowStable
Top Statement Risk

Greater China regulatory exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Remains Highly Volatile

According to recent financial statements, USANA's revenue growth has exhibited significant inconsistency, oscillating between a 10.8% expansion in 2025Q2 and a 6.2% contraction in 2024Q3, suggesting that the company's reliance on the Greater China market creates unpredictable top-line performance tied to regional economic and regulatory shifts.

The fluctuation in quarterly revenue growth indicates that the company's core direct-selling model is struggling to maintain a consistent trajectory in its primary markets. Investors should monitor whether the recent return to positive growth in early 2026 represents a sustainable recovery or merely a temporary rebound from prior-year weakness.

Gross Margin Resilience Masks Profitability

As reported in recent filings, USANA maintains a robust gross margin profile averaging near 78%, yet this structural strength is increasingly disconnected from bottom-line results, as net margins have compressed to as low as -3.1% in 2025Q3 due to elevated operating costs and incentive payouts.

The persistent gap between high gross margins and thin net profitability suggests that the company's cost of maintaining its Associate network is disproportionately high relative to the value captured. This divergence implies that the business model may be facing structural headwinds that prevent the conversion of premium product pricing into meaningful shareholder earnings.

Operating Leverage Remains Under Pressure

Based on the provided income statement data, USANA's operating income has failed to scale efficiently with revenue, as evidenced by operating margins dropping from 11.0% in 2023Q4 to 5.5% in 2026Q1, indicating that SG&A expenses are consuming an increasing share of the company's gross profit.

The inability to achieve operating leverage suggests that the company is forced to reinvest heavily in its distribution network just to maintain current revenue levels. This trend warrants further investigation into whether the current commission structure is becoming a permanent drag on the company's ability to generate operating income.

Earnings Quality Impacted by Volatility

Analysis of the reported figures reveals that USANA's net income has been significantly impacted by non-operating items and periodic losses, with net margins swinging from a 7.6% profit in 2023Q4 to a net loss of $6.5 million in 2025Q3, highlighting the fragility of the company's bottom-line performance.

The erratic nature of net income suggests that the company's earnings are highly sensitive to operational disruptions and potential inventory loading dynamics. Investors should be cautious of the reported EPS, as the volatility in net income makes it a less reliable indicator of the company's underlying long-term earning power.

Sustainability of Distribution Model Challenged

While USANA maintains a fortress balance sheet with minimal debt, the income statement suggests a potential long-term risk, as the company's reliance on high commission payouts to sustain its Associate base may be reaching a point of diminishing returns in a competitive e-commerce environment.

Short-term observers might focus on the company's cash position, but the fundamental concern remains the erosion of net margins and the potential for regulatory intervention in its primary markets. If the company cannot improve its operating efficiency, the current business model may face a permanent reset in its ability to deliver value to shareholders.

USNA — Frequently Asked Questions

Quick answers to the most common questions about buying USNA stock.

What was USANA Health Sciences, Inc.'s (USNA) revenue in 2025?

For fiscal year 2025, USANA Health Sciences, Inc. (USNA) reported total revenue of $925.3M. This represents a 1531.8% increase compared to $56.7M in 1996.

Is USANA Health Sciences, Inc. (USNA) profitable?

USANA Health Sciences, Inc. (USNA) is profitable, generating $10.8M in net income for the fiscal year ending 2025 with a net profit margin of 1.2%.

What is USANA Health Sciences, Inc.'s operating profit margin?

USANA Health Sciences, Inc. (USNA) reported an operating income of $50.9M, resulting in an operating profit margin of 5.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is USANA Health Sciences, Inc.'s gross profit and gross margin?

USANA Health Sciences, Inc. (USNA) generated $724.4M in gross profit for the year, representing a gross profit margin of 78.3%. This demonstrates the company's core pricing power and production efficiency.